Clear Street raised the firm’s price target on Ocular Therapeutix (OCUL) to $21 from $18 and keeps a Buy rating on the shares after the company reported Q3 results and announced that SOL-R, the second registrational trial of AXPAXLI in wet age-related macular degeneration, has completed target randomization. Ocular’s clinical trial execution for AXPAXLI has “continued to impress,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix’s Strategic Positioning and High Success Probability Support Buy Rating
- Ocular Therapeutix: Strong Execution and Promising Growth Prospects Justify Buy Rating
- Ocular Therapeutix achieves target randomization of 555 subjects in SOL-R
- Ocular Therapeutix reports Q3 EPS (38c), consensus (35c)
- OCUL Earnings this Week: How Will it Perform?